Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

18.97 +0.45 (+2.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 771,397
Open 18.38
Bid (Size) 18.59 (8)
Ask (Size) 19.30 (3)
Prev. Close 18.52
Today's Range 17.88 - 19.01
52wk Range 15.45 - 33.31
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-31.34%
-31.34%
1 Month
-3.16%
-3.16%
3 Month
-20.43%
-20.43%
6 Month
-41.61%
-41.61%
1 Year
-41.86%
-41.86%

More News

Read More
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Expectations for Denali Therapeutics's Future
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future
Via Benzinga
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
From Denali Therapeutics Inc.
Via GlobeNewswire
Why Shares of Denali Therapeutics Are Up Monday
Via The Motley Fool
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
Via InvestorPlace
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
Via Benzinga
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Via MarketBeat
Exposures Product Safety
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Biogen Moves Deeper In Alzheimer's With Denali
Via Talk Markets
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
Via Benzinga
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.